14-day Premium Trial Subscription Sign Up For FreeGet Free

Benitec Biopharma Limited Stock Forecast NASDAQ:BNTC

$2.39 (-6.64%)

Volume: 49k

Closed: Jan 18, 2022

Hollow Logo Score: -5.452

Benitec Biopharma Limited Stock Forecast

$2.39 (-6.64%)

Volume: 49k

Closed: Jan 18, 2022

Score Hollow Logo -5.452

Benitec Biopharma Limited Company Profile

F6A/1-15 Barr Street

Sydney NSW 2041

61 2 9555 6986


Industry: Biotechnology

Sector: Healthcare

Benitec Biopharma Limited


Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing technology, DNA-directed RNA interference (ddRNAi) in Australia. Its in-house development programs include TT-034, which is in Phase I/IIa clinical trials for the treatment of hepatitis C; Hepbarna for the treatment of the hepatitis B virus; Tribetarna for treating drug resistant non-small cell lung cancer; and Pabparna to treat oculopharyngeal muscular dystrophy, an autosomal-dominant inherited, slow-progressing, and late-onset degenerative muscle disorder that occurs at the age of 40 or 50 years in patients, as well as a single dose treatment for wet age-related macular degeneration. The company also licenses its ddRNAi technology to other biopharmaceutical companies for various clinical applications comprising HIV/AIDS, cancer immunotherapy, retinitis pigmentosa, huntington’s diseases, and intractable neuropathic pain. Benitec Biopharma Limited was founded in 1997 and is headquartered in Sydney, Australia.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE